Milestone Scientific sees $78,713 stock sale by BP4 S.r.l.

Milestone Scientific Inc. (NYSE:MLSS), a medical device company with a market capitalization of $71.4 million, recently witnessed significant stock transactions by BP4 S.r.l., a major stakeholder. According to InvestingPro data, the company currently trades at a Price/Book multiple of 16x and maintains a Fair Value rating suggesting it may be overvalued at current levels. According to a recent SEC filing, BP4 S.r.l. sold a total of 87,055 shares over two days, resulting in a total sale value of $78,713.

On June 5, BP4 S.r.l. sold 26,855 shares at a price of $0.9104 per share. The following day, June 6, the firm offloaded an additional 60,200 shares at a slightly lower price of $0.9014 per share. After these transactions, BP4 S.r.l. holds 9,531,402 shares of Milestone Scientific.

These transactions were executed under direct ownership, as indicated in the filing. The liquidator for BP4 S.r.l., Dr. Pedro Palau, signed off on the transactions on June 10, 2025. The company maintains a moderate debt level with a debt-to-equity ratio of 0.07 and receives a "FAIR" overall Financial Health score from InvestingPro.

In other recent news, Milestone Scientific Inc. has made significant strides in its financial and strategic endeavors. The company concluded the first quarter with $2.2 million in cash and no debt, as reported by Benchmark analysts, who have maintained a Speculative Buy rating and a price target of $1.25 on the company’s shares. Milestone Scientific is actively working to expand its Medicare market segment for pain management with its CompuFlo System, which currently has coverage from three out of twelve Medicare Administrative Contractors. This strategic push is aimed at capturing a market that accounts for approximately 3.6 million procedures annually, with plans to secure coverage from the remaining nine MACs and private payors. Additionally, Milestone Scientific has appointed Shanth Thiyagalingam to its Board of Directors to drive growth, given his extensive experience in the medical device and pharmaceutical sectors. Thiyagalingam’s expertise in commercial scaling and reimbursement strategy is expected to bolster the company’s expansion efforts. The company’s focus on innovative injection technologies, particularly its DPS Dynamic Pressure Sensing Technology, remains a core aspect of its product development strategy. Benchmark’s analysts have reiterated their Buy rating, citing the company’s strategic plans and financial position as key factors for their continued support.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.